CVS Well being mentioned Wednesday that demand for at-home Covid checks and booster pictures lifted total retailer gross sales, serving to the corporate prime expectations for fourth-quarter Earnings.

Shares fell lower than 1% in premarket buying and selling.

The pharmacy chain and well being insurer reiterated its fiscal 2022 forecast, saying it expects earnings from persevering with operations to vary between $7.04 to $7.24 per share and adjusted earnings to vary between $8.10 to $8.30 per share.

This is what the corporate reported for the three-month interval ended Dec. 31, in contrast with what analysts have been anticipating, based mostly on a survey of analysts by Refinitiv:

• Earnings per share: $1.98 adjusted vs. $1.93 anticipated
• Income: $76.60 billion vs. $75.67 billion anticipated

CVS reported fiscal fourth-quarter web revenue of $1.31 billion, or 99 cents per share, up from $973 million, or 74 cents per share, a 12 months earlier.

The corporate mentioned its web revenue from persevering with operations was 98 cents. However it earned $1.98 per share, after changes, which was greater than the $1.93 per share anticipated by analysts surveyed by Refinitiv.

Complete income for the interval rose to $76.60 billion from $69.55 billion a 12 months earlier, exceeding expectations of $75.67 billion.

CVS mentioned it noticed greater prescription volumes, front-of-store gross sales and vaccinations at its shops through the three month interval. It mentioned it additionally benefited from the expansion of specialty pharmacy.

It administered greater than 8 million Covid checks and greater than 20 million Covid vaccines throughout the nation within the fourth quarter, a big soar in vaccinations from the 11.6 million it administered within the third quarter.

Shares of CVS are up 51% over the previous 12 months and touched a 52-week excessive on Tuesday. Shares closed Tuesday at $110.83, up 1.3%. The corporate’s market worth is $146.30 billion.

Learn the corporate’s press launch right here.